$FENC
FENNEC PHARMACEUTICALS INC.

2024 Q4 Form 10-Q Financial Statement

#000155837024015068 Filed on November 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $6.974M
YoY Change 7.05%
Cost Of Revenue $1.357M
YoY Change 309.97%
Gross Profit $5.617M
YoY Change -9.17%
Gross Profit Margin 80.54%
Selling, General & Admin $10.72M
YoY Change 49.14%
% of Gross Profit 190.88%
Research & Development $97.00K
YoY Change 708.33%
% of Gross Profit 1.73%
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $12.18M
YoY Change 69.09%
Operating Profit -$5.202M
YoY Change 411.5%
Interest Expense -$533.0K
YoY Change -37.29%
% of Operating Profit
Other Income/Expense, Net -$533.0K
YoY Change -37.29%
Pretax Income -$5.735M
YoY Change 206.68%
Income Tax
% Of Pretax Income
Net Earnings -$5.735M
YoY Change 207.18%
Net Earnings / Revenue -82.23%
Basic Earnings Per Share -$0.21
Diluted Earnings Per Share -$0.21
COMMON SHARES
Basic Shares Outstanding 27.43M 27.36M
Diluted Shares Outstanding 27.37M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $40.32M
YoY Change 225.16%
Cash & Equivalents $40.32M
Short-Term Investments
Other Short-Term Assets $546.0K
YoY Change 2630.0%
Inventory $1.125M
Prepaid Expenses $3.066M
Receivables $12.91M
Other Receivables $0.00
Total Short-Term Assets $57.97M
YoY Change 205.95%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $956.0K
YoY Change 1812.0%
Total Long-Term Assets $956.0K
YoY Change 1065.85%
TOTAL ASSETS
Total Short-Term Assets $57.97M
Total Long-Term Assets $956.0K
Total Assets $58.92M
YoY Change 209.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.867M
YoY Change 31.49%
Accrued Expenses $3.313M
YoY Change 248.37%
Deferred Revenue $248.0K
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.435M
YoY Change 90.01%
LONG-TERM LIABILITIES
Long-Term Debt $30.00M
YoY Change 20.0%
Other Long-Term Liabilities $26.66M
YoY Change 4001.08%
Total Long-Term Liabilities $56.66M
YoY Change 120.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.435M
Total Long-Term Liabilities $56.66M
Total Liabilities $64.09M
YoY Change 116.83%
SHAREHOLDERS EQUITY
Retained Earnings -$217.7M
YoY Change 0.52%
Common Stock $211.3M
YoY Change 3.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$5.171M
YoY Change
Total Liabilities & Shareholders Equity $58.92M
YoY Change 209.65%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$5.735M
YoY Change 207.18%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.206M
YoY Change -20.07%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -528.0K
YoY Change -364.0%
NET CHANGE
Cash From Operating Activities -2.206M
Cash From Investing Activities
Cash From Financing Activities -528.0K
Net Change In Cash -2.734M
YoY Change 6.8%
FREE CASH FLOW
Cash From Operating Activities -$2.206M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001211583
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Trading Symbol
TradingSymbol
FENCF
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27422000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27027000
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
fenc Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
0
fenc Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
0
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-32295
dei Entity Registrant Name
EntityRegistrantName
FENNEC PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
CA
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0442384
dei Entity Address Address Line1
EntityAddressAddressLine1
PO Box 13628, 68 TW Alexander Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Research Triangle Park
dei Entity Address State Or Province
EntityAddressStateOrProvince
NC
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
27709
dei City Area Code
CityAreaCode
919
dei Local Phone Number
LocalPhoneNumber
636-4530
dei Security12b Title
Security12bTitle
Common Shares, no par value
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
27432234
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40320000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13269000
CY2024Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
12908000
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
8814000
CY2024Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3066000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2575000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1125000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2156000
CY2024Q3 us-gaap Other Assets Current
OtherAssetsCurrent
546000
CY2023Q4 us-gaap Other Assets Current
OtherAssetsCurrent
44000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
57965000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
26858000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
956000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
6000
CY2024Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
956000
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
6000
CY2024Q3 us-gaap Assets
Assets
58921000
CY2023Q4 us-gaap Assets
Assets
26864000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
3867000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3778000
CY2024Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3313000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3754000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
21000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
248000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
7435000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7553000
CY2024Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2023Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2024Q3 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
2323000
CY2023Q4 us-gaap Interest Payable Current And Noncurrent
InterestPayableCurrentAndNoncurrent
1219000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
227000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
288000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
24561000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
2000
CY2024Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
56657000
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
30933000
CY2024Q3 us-gaap Liabilities
Liabilities
64092000
CY2023Q4 us-gaap Liabilities
Liabilities
38486000
CY2024Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27422000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27027000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
145438000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
144307000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
65844000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
62073000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217696000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-219245000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1243000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5171000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11622000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58921000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
26864000
CY2024Q3 fenc Pedmark Revenue
PedmarkRevenue
6974000
CY2023Q3 fenc Pedmark Revenue
PedmarkRevenue
6515000
fenc Pedmark Revenue
PedmarkRevenue
21655000
fenc Pedmark Revenue
PedmarkRevenue
11517000
fenc Licensing Revenue Pedmark
LicensingRevenuePedmark
17958000
CY2024Q3 us-gaap Revenues
Revenues
6974000
CY2023Q3 us-gaap Revenues
Revenues
6515000
us-gaap Revenues
Revenues
39613000
us-gaap Revenues
Revenues
11517000
CY2024Q3 fenc Cost Of Product Sales
CostOfProductSales
1357000
CY2023Q3 fenc Cost Of Product Sales
CostOfProductSales
331000
fenc Cost Of Product Sales
CostOfProductSales
2515000
fenc Cost Of Product Sales
CostOfProductSales
574000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
97000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
257000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
4601000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
3384000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
14482000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8255000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6121000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3805000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18857000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13617000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
12176000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
7532000
us-gaap Operating Expenses
OperatingExpenses
36111000
us-gaap Operating Expenses
OperatingExpenses
22470000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5202000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1017000
us-gaap Operating Income Loss
OperatingIncomeLoss
3502000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10953000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-11000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-55000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
3000
CY2024Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
21000
CY2023Q3 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
72000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
64000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
217000
CY2024Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q3 us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
13000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
14000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
43000
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
516000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
102000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1283000
us-gaap Investment Income Interest
InvestmentIncomeInterest
326000
CY2024Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
1025000
CY2023Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
856000
us-gaap Interest Expense Debt
InterestExpenseDebt
3103000
us-gaap Interest Expense Debt
InterestExpenseDebt
2479000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-533000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-850000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1953000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2410000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5735000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1867000
us-gaap Net Income Loss
NetIncomeLoss
1549000
us-gaap Net Income Loss
NetIncomeLoss
-13363000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27371000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26596000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27371000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26523000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27371000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26596000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28015000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26523000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-11622000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
19000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
12837000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
3014000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
347000
CY2024Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
90000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-5553000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-1357000
CY2024Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
157000
CY2024Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
57000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5735000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
-5171000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-2569000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
213000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
20000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6052000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-7339000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
541000
CY2023Q2 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
28000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-5444000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-9727000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
215000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
17000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1867000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-10531000
us-gaap Profit Loss
ProfitLoss
1549000
us-gaap Profit Loss
ProfitLoss
-13363000
us-gaap Inventory Write Down
InventoryWriteDown
517000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
3604000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
64000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
51000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
14000
us-gaap Available For Sale Debt Securities Gross Unrealized Loss
AvailableForSaleDebtSecuritiesGrossUnrealizedLoss
43000
fenc Amortization Of Norgine Asset
AmortizationOfNorgineAsset
774000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
166000
fenc Payment Of Pik Interest
PaymentOfPikInterest
1104000
fenc Payment Of Pik Interest
PaymentOfPikInterest
677000
us-gaap Share Based Compensation
ShareBasedCompensation
3937000
us-gaap Share Based Compensation
ShareBasedCompensation
4497000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7698000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2980000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
491000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-523000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-514000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1179000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-109000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
89000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
551000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-441000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1269000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
24809000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28454000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-12283000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
504000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
969000
fenc Cash Paid For Taxes On Restricted Share Release
CashPaidForTaxesOnRestrictedShareRelease
167000
fenc Cash Paid For Taxes On Restricted Share Release
CashPaidForTaxesOnRestrictedShareRelease
61000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
1740000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1403000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
908000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
27051000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11375000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13269000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23774000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40320000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12399000
fenc Capitalized Lease Asset
CapitalizedLeaseAsset
21000
fenc Capitalized Lease Asset
CapitalizedLeaseAsset
29000
us-gaap Nature Of Operations
NatureOfOperations
<table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Nature of Business and Going Concern</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fennec Pharmaceuticals Inc., a corporation existing under the laws of British Columbia (“Fennec,” the “Company,” “we,” “us,” or “our”), was originally formed under the name Adherex Technologies Inc. and subsequently changed its name on September 3, 2014. Fennec is a commercial stage specialty pharmaceutical company with one U.S. Food and Drug Administration (“FDA”) approved and European Commission approved product, PEDMARK<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> in the U.S. and PEDMARQSI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> the European branded name for PEDMARK<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (collectively, “PEDMARK”), developed to reduce the risk of ototoxicity associated with cisplatin in pediatric patients one month of age and older with localized, non-metastatic solid tumors. The Company has four wholly owned subsidiaries: Oxiquant, Inc. (“Oxiquant”) and Fennec Pharmaceuticals, Inc., both Delaware corporations, Cadherin Biomedical Inc. (“CBI”), a Canadian corporation, and Fennec Pharmaceuticals (EU) Limited (“Fennec Limited”), an Ireland company, collectively referred to herein as the “Company.” With the exception of Fennec Pharmaceuticals, Inc. and Fennec Limited all subsidiaries are inactive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">These unaudited interim condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”) that are applicable to a going concern which contemplates that the Company will continue in operation for the foreseeable future and will be able to realize its assets and discharge its liabilities in the normal course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three and nine-month period ended September 30, 2024, the Company earned a (loss)/income from operations of $(5,202) and $3,502 respectively. At September 30, 2024, it had an accumulated deficit of $217,696 and had experienced positive cash flows from operating activities during the nine months ended September 30, 2024, in the amount of $28,454.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On August 1, 2022, the Company entered into a Securities Purchase Agreement (the “SPA”) with Petrichor Opportunities Fund I LP (the “Investor”) in connection with the issuance of up to $45,000 of senior secured floating rate convertible notes (the “Notes”), issuable in multiple tranches (the “Note Financing”). On August 19, 2022, the Company closed on the initial tranche of $5,000 (the “First Closing Note”) which has an Initial Conversion Price equal to $8.11 per share, which was calculated based on a 20% premium of the 5-day volume weighted average price of the Company’s common shares as traded on the Nasdaq Capital Market (the “VWAP”) immediately prior to the announcement of the SPA dated August 1, 2022. In connection with the closing of the First Closing Note, the Company repaid in full its secured indebtedness with Bridge Bank in the amount of $5,000. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On September 23, 2022, the Company closed on the second tranche of the Note Financing in the amount of $20,000 (the “Second Closing Note”), which has an Initial Conversion Price equal to $7.89 per share, which was calculated based on a 20% premium of the 5-day VWAP immediately prior to September 20, 2022, which was the date the Company obtained FDA approval of PEDMARK. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SPA provided that subsequent to the funding of the Second Closing Note, and before December 31, 2023, the Company could draw up to $20,000 of additional financing under the SPA, in one or more tranches of $10,000 upon mutual agreement of the Company and the Investor (the “Subsequent Closing Notes”). The Subsequent Closing Notes will be convertible at a price per share equal to $7.89 per share, which price is calculated on the same basis as for the Second Closing Note.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A commitment fee of 2.0% of the Notes was payable under the SPA, which was paid by the Company issuing the Investor warrants to purchase 110,996 of the Company’s common shares (one <span style="-sec-ix-hidden:Hidden_3ZXZY_30nEm4ZkzAtietzg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">half</span></span> issued at the closing of the First Closing Note and the other <span style="-sec-ix-hidden:Hidden_DwwSjYe0lUuIOkoI2yJACg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">half</span></span>  issued at the closing of the Second Closing Note).The warrants are exercisable at a price per share of $8.11 and have a term of five years from the date of the grant.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 4, 2023, the Company closed the third tranche of the Note Financing in the amount of $5,000 (the “Third Closing Note”) which is convertible at a price equal to $7.89 per share, calculated as a 20% premium of the 5-day VWAP immediately prior to September 20, 2022, which was the date the Company obtained FDA approval of PEDMARK.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Also on December 4, 2023, the Company entered into a First Amendment to the Securities Purchase Agreement (the “SPA Amendment”) with the Investor, which, among other things, extends the period that the Company may draw the remaining $15,000 under the SPA from December 31, 2023, to December 31, 2024. Subsequent draws are subject to mutual agreement of the Company and the Investor and will be represented by Notes that will also be convertible at a price equal to $7.89 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On March 17, 2024, the Company announced it had entered into an exclusive licensing agreement with Norgine Pharma UK Limited (“Norgine”) to commercialize PEDMARQSI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup> (EU brand name for PEDMARK) in Europe, New Zealand and Australia. The licensing agreement provided Fennec with approximately $43,200 up front and may provide Fennec with up to approximately $230,000 in milestone and royalty payments in the future. On July 26, 2024, Norgine and Fennec amended the exclusive licensing agreement. The amended agreement maintains all principal payment terms with the primary addition of Norgine assuming responsibility for packaging and labeling of PEDMARQSI<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">®</sup>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company believes current funds provide sufficient funding for the Company to carry out its planned activities, including the continuation of commercialization efforts of PEDMARK, for at least the next twelve months and into 2026.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">These financial statements do not reflect the potentially material adjustments in the carrying values of assets and liabilities, the reported expenses, and the balance sheet classifications used, that would be necessary if the going concern assumption were not appropriate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p>
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5202000
us-gaap Operating Income Loss
OperatingIncomeLoss
3502000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217696000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
28454000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that impact the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the consolidated financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include revenue recognition, allowance against trade receivables, measurement of stock-based compensation and estimates of the Company’s capital requirements over the next twelve months from the date of issuance of the consolidated financial statements. Actual results could differ from those estimates.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
fenc Percentage Of Prompt Payment Discounts Expected To Pay Out
PercentageOfPromptPaymentDiscountsExpectedToPayOut
1
CY2023Q4 fenc Provision For Discounts And Allowances
ProvisionForDiscountsAndAllowances
795000
CY2024Q1 fenc Discounts And Allowances Provision For Current Period Sales
DiscountsAndAllowancesProvisionForCurrentPeriodSales
1992000
CY2024Q1 fenc Discounts And Allowances Payments And Customer Credits Issued
DiscountsAndAllowancesPaymentsAndCustomerCreditsIssued
601000
CY2024Q1 fenc Provision For Discounts And Allowances
ProvisionForDiscountsAndAllowances
2186000
CY2024Q2 fenc Discounts And Allowances Provision For Current Period Sales
DiscountsAndAllowancesProvisionForCurrentPeriodSales
2819000
CY2024Q2 fenc Discounts And Allowances Payments And Customer Credits Issued
DiscountsAndAllowancesPaymentsAndCustomerCreditsIssued
2680000
CY2024Q2 fenc Provision For Discounts And Allowances
ProvisionForDiscountsAndAllowances
2325000
CY2024Q3 fenc Discounts And Allowances Provision For Current Period Sales
DiscountsAndAllowancesProvisionForCurrentPeriodSales
1165000
CY2024Q3 fenc Discounts And Allowances Payments And Customer Credits Issued
DiscountsAndAllowancesPaymentsAndCustomerCreditsIssued
1793000
CY2024Q3 fenc Provision For Discounts And Allowances
ProvisionForDiscountsAndAllowances
1697000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4971000
CY2024Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000000
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Concentrations of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Financial instruments that potentially subject the Company to credit risk primarily consist of cash and cash equivalents, and accounts receivable. The Company maintains deposits in highly rated, federally-insured financial institutions in excess of federally insured limits. The Company’s investment strategy is focused on capital preservation. The Company invests in instruments that meet the high credit quality standards outlined in the Company’s investment policy. This policy also limits the amount of credit exposure to any one issue or type of instrument.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company’s trade receivables includes amounts billed to customers for product sales of PEDMARK. In the U.S., the customers are a limited group of specialty distributors, and accordingly, the Company considers the risk of potential credit losses to be low. The Company also sells to a select group of global distributors. These global distributors are established companies and although the Company regards credit losses with these distributors to be remote, it does recognize the potential for credit losses with this group.</span></p>
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-5735000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1867000
us-gaap Net Income Loss
NetIncomeLoss
1549000
us-gaap Net Income Loss
NetIncomeLoss
-13363000
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27371000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26596000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
27371000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
26523000
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
620000
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
24000
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
27371000
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26596000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
28015000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
26523000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.06
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
CY2024Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
1821000
CY2023Q3 us-gaap Stock Option Plan Expense
StockOptionPlanExpense
865000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
3937000
us-gaap Stock Option Plan Expense
StockOptionPlanExpense
4497000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2024Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
40320000
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
13269000
CY2024Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
2000
CY2023Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
17000
CY2024Q3 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2024Q3 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.10
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
5000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2000
CY2024Q3 fenc Lease Liabilities To Be Paid Before Imputed Interest
LeaseLiabilitiesToBePaidBeforeImputedInterest
7000
CY2024Q3 fenc Lease Liabilities Imputed Interest
LeaseLiabilitiesImputedInterest
2000
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
5000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
7000
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
7000
CY2024Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
30000000
CY2024Q3 fenc Payment Of In Kind Interest
PaymentOfInKindInterest
2323000
CY2024Q3 fenc Debt Instrument Total Future Payments Due
DebtInstrumentTotalFuturePaymentsDue
32323000
CY2024Q3 fenc Unamortized Debt Discount
UnamortizedDebtDiscount
227000
CY2024Q3 us-gaap Long Term Debt
LongTermDebt
32096000

Files In Submission

Name View Source Status
fencf-20240930x10q_htm.xml Edgar Link completed
0001558370-24-015068-index-headers.html Edgar Link pending
0001558370-24-015068-index.html Edgar Link pending
0001558370-24-015068.txt Edgar Link pending
0001558370-24-015068-xbrl.zip Edgar Link pending
fencf-20240930.xsd Edgar Link pending
fencf-20240930x10q.htm Edgar Link pending
fencf-20240930xex31d1.htm Edgar Link pending
fencf-20240930xex31d2.htm Edgar Link pending
fencf-20240930xex32d1.htm Edgar Link pending
fencf-20240930xex99d1.htm Edgar Link pending
fencf-20240930xex99d1001.jpg Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
fencf-20240930_lab.xml Edgar Link unprocessable
fencf-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
fencf-20240930_cal.xml Edgar Link unprocessable
fencf-20240930_def.xml Edgar Link unprocessable